<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://articlefeeds.nasdaq.com/~d/styles/itemcontent.css"?><rss xmlns:a10="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
  <channel xmlns:nasdaq="http://nasdaq.com/reference/feeds/1.0/">
    <title>Latest Articles about EXAC</title>
    <description />
    <language>EN-US</language>
    <lastBuildDate>Mon, 20 May 2013 00:57:15 -0400</lastBuildDate>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://articlefeeds.nasdaq.com/nasdaq/symbols?symbol=EXAC" /><feedburner:info uri="nasdaq/symbols" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item xml:base="http://www.nasdaq.com/article/covidiens-2q-earnings-beat-analyst-blog-cm241258">
      <guid isPermaLink="false">241258</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GHdOXUSpsfs/covidiens-2q-earnings-beat-analyst-blog-cm241258</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>Covidien's 2Q Earnings Beat - Analyst Blog</title>
      <description>Covidien plc.  's (  COV  ) adjusted earnings  per share (EPS) from continuing operations of $1.12 for the second  quarter of fiscal 2013 beat the Zacks Consensus Estimate of $1.10  by 1.8%.&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/GHdOXUSpsfs" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 26 Apr 2013 23:40:01 Z</pubDate>
      <a10:updated>2013-04-26T20:28:47Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>COV</nasdaq:tickers>
      <nasdaq:tickers>EPS</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
      <nasdaq:tickers>PRGO</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/covidiens-2q-earnings-beat-analyst-blog-cm241258</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/zimmer-beats-earnings-misses-revenue-analyst-blog-cm240713">
      <guid isPermaLink="false">240713</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g8DGoTciwec/zimmer-beats-earnings-misses-revenue-analyst-blog-cm240713</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>Zimmer Beats Earnings, Misses Revenue - Analyst Blog</title>
      <description>Zimmer Holdings  (  ZMH  ) reported adjusted  earnings at $1.41, up 8.5% year over year, as well as a penny ahead  of the Zacks Consensus Estimate. However, after including one-time  items,&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/g8DGoTciwec" height="1" width="1"/&gt;</description>
      <pubDate>Thu, 25 Apr 2013 20:06:01 Z</pubDate>
      <a10:updated>2013-04-25T16:33:30Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
      <nasdaq:tickers>SNN</nasdaq:tickers>
      <nasdaq:tickers>ZMH</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/zimmer-beats-earnings-misses-revenue-analyst-blog-cm240713</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/edwards-lags-on-earnings-rev-analyst-blog-cm240090">
      <guid isPermaLink="false">240090</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UdAXYyV9Tlo/edwards-lags-on-earnings-rev-analyst-blog-cm240090</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>Edwards Lags on Earnings &amp; Rev - Analyst Blog</title>
      <description>Edwards Lifesciences Corporation's  (  EW  ) first-quarter 2013 adjusted earnings per share (EPS) came in at 72 cents, up 35.8% year over year, but lagging the Zacks Consensus Estimate of 76&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/UdAXYyV9Tlo" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 24 Apr 2013 18:14:58 Z</pubDate>
      <a10:updated>2013-04-24T15:18:21Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>EPS</nasdaq:tickers>
      <nasdaq:tickers>EW</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>MDT</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/edwards-lags-on-earnings-rev-analyst-blog-cm240090</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/new-product-from-abbott-labs-analyst-blog-cm239315">
      <guid isPermaLink="false">239315</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BD25ErV9zt8/new-product-from-abbott-labs-analyst-blog-cm239315</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>New Product from Abbott Labs  - Analyst Blog</title>
      <description>Abbott Laboratories  (  ABT  ) recently announced that the company has gained approval from the US Food and Drug Administration (FDA) for its TECNIS Toric 1-Piece intraocular lens (IOL). The&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/BD25ErV9zt8" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 23 Apr 2013 02:09:40 Z</pubDate>
      <a10:updated>2013-04-22T23:12:15Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ABBV</nasdaq:tickers>
      <nasdaq:tickers>ABT</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/new-product-from-abbott-labs-analyst-blog-cm239315</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/abbott-labs-recalls-glucose-meter-analyst-blog-cm238825">
      <guid isPermaLink="false">238825</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gNybPvM5v0w/abbott-labs-recalls-glucose-meter-analyst-blog-cm238825</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Abbott Labs Recalls Glucose Meter  - Analyst Blog</title>
      <description>Abbott Laboratories  (  ABT  ) recently announced that the company is initiating a voluntary recall of its FreeStyle InsuLinx Blood Glucose Meters in the US.  Abbott Labs decided to recall the&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/gNybPvM5v0w" height="1" width="1"/&gt;</description>
      <pubDate>Sat, 20 Apr 2013 01:12:50 Z</pubDate>
      <a10:updated>2013-04-19T22:17:43Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ABBV</nasdaq:tickers>
      <nasdaq:tickers>ABT</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/abbott-labs-recalls-glucose-meter-analyst-blog-cm238825</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/covidien-collaborates-with-vida-analyst-blog-cm237822">
      <guid isPermaLink="false">237822</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T_D8LSPaO6g/covidien-collaborates-with-vida-analyst-blog-cm237822</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Covidien Collaborates with VIDA - Analyst Blog</title>
      <description>International healthcare major,  Covidien plc  (  COV  ) has inked an agreement with leading pulmonary imaging software service provider, VIDA Diagnostics. As per the agreement, Covidien will&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/T_D8LSPaO6g" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 17 Apr 2013 22:10:42 Z</pubDate>
      <a10:updated>2013-04-17T19:16:13Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>COV</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
      <nasdaq:tickers>PRGO</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/covidien-collaborates-with-vida-analyst-blog-cm237822</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/st-judes-1q-earnings-in-line-analyst-blog-cm237802">
      <guid isPermaLink="false">237802</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MQIJKVOJJOc/st-judes-1q-earnings-in-line-analyst-blog-cm237802</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>St. Jude's 1Q Earnings In Line - Analyst Blog</title>
      <description>St. Jude Medical  's (  STJ  ) first-quarter  adjusted earnings per share of 92 cents were in line with the Zacks  Consensus Estimate and transcended the year-ago earnings of 86  cents.&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/MQIJKVOJJOc" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 17 Apr 2013 21:20:41 Z</pubDate>
      <a10:updated>2013-04-17T17:20:52Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AF</nasdaq:tickers>
      <nasdaq:tickers>CRM</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
      <nasdaq:tickers>PRGO</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/st-judes-1q-earnings-in-line-analyst-blog-cm237802</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/abbott-reports-inline-1q-earnings-analyst-blog-cm237783">
      <guid isPermaLink="false">237783</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DZlZ5JkjCSI/abbott-reports-inline-1q-earnings-analyst-blog-cm237783</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>Abbott Reports In-Line 1Q Earnings  - Analyst Blog</title>
      <description>Abbott Laboratories  (  ABT  ) reported first quarter 2013 earnings of 42 cents per share, in line with the Zacks Consensus Estimate and 5.0% above the year-ago earnings. Including one-time&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/DZlZ5JkjCSI" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 17 Apr 2013 21:13:30 Z</pubDate>
      <a10:updated>2013-04-17T18:17:28Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ABBV</nasdaq:tickers>
      <nasdaq:tickers>ABT</nasdaq:tickers>
      <nasdaq:tickers>EPD</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>NUVA</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/abbott-reports-inline-1q-earnings-analyst-blog-cm237783</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/hanger-meets-on-eps-sales-lag-analyst-blog-cm186266">
      <guid isPermaLink="false">186266</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Le-AHDVV3iI/hanger-meets-on-eps-sales-lag-analyst-blog-cm186266</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Hanger Meets on EPS, Sales Lag - Analyst Blog</title>
      <description>Hanger  Inc.  's (  HGR  ) reported earnings of 50 cents per share for third quarter of 2012 were in line with the Zacks Consensus Estimate. However, it exceeded the year-ago adjusted earnings&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Le-AHDVV3iI" height="1" width="1"/&gt;</description>
      <pubDate>Thu, 01 Nov 2012 17:28:29 Z</pubDate>
      <a10:updated>2012-11-01T14:33:44Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CNMD</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>HGR</nasdaq:tickers>
      <nasdaq:tickers>OFIX</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/hanger-meets-on-eps-sales-lag-analyst-blog-cm186266</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/hanger-retained-at-neutral-analyst-blog-cm169868">
      <guid isPermaLink="false">169868</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dJSlM1UMhmU/hanger-retained-at-neutral-analyst-blog-cm169868</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Hanger Retained at Neutral - Analyst Blog</title>
      <description>We reiterate our Neutral recommendation on  Hanger Inc  (  HGR  ) following its second quarter results which surpassed the Zacks Consensus Estimates.  The company's adjusted earnings of 50 cents&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/dJSlM1UMhmU" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 04 Sep 2012 21:33:23 Z</pubDate>
      <a10:updated>2012-09-04T18:36:51Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>HGR</nasdaq:tickers>
      <nasdaq:tickers>OFIX</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/hanger-retained-at-neutral-analyst-blog-cm169868</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/zacks-5-rank-additions-for-friday-tale-of-the-tape-cm161134">
      <guid isPermaLink="false">161134</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hecyLlVxnOM/zacks-5-rank-additions-for-friday-tale-of-the-tape-cm161134</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <category>Stocks</category>
      <title>Zacks #5 Rank Additions for Friday  - Tale of the Tape</title>
      <description>Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List today:    AMERICAN SANDS ENGY CORP.  (  AMSE  )   Itau Unibanco Holding SA (ADR)  (  ITUB  )   Dynamic Materials Corp.&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/hecyLlVxnOM" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 03 Aug 2012 17:14:01 Z</pubDate>
      <a10:updated>2012-08-03T14:25:28Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AMSE</nasdaq:tickers>
      <nasdaq:tickers>BOOM</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>GMCR</nasdaq:tickers>
      <nasdaq:tickers>ITUB</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/zacks-5-rank-additions-for-friday-tale-of-the-tape-cm161134</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/hanger-beats-raises-eps-guidance-analyst-blog-cm160802">
      <guid isPermaLink="false">160802</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4VMNoL2YG8g/hanger-beats-raises-eps-guidance-analyst-blog-cm160802</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Hanger Beats, Raises EPS Guidance - Analyst Blog</title>
      <description>Hanger Orthopedic Group Inc.  (  HGR  ) reported second quarter 2012 adjusted earnings of 50 cents per share, beating the Zacks Consensus Estimate by a penny and exceeding the year-ago adjusted&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/4VMNoL2YG8g" height="1" width="1"/&gt;</description>
      <pubDate>Thu, 02 Aug 2012 18:22:03 Z</pubDate>
      <a10:updated>2012-08-02T15:24:05Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CNMD</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>HGR</nasdaq:tickers>
      <nasdaq:tickers>OFIX</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/hanger-beats-raises-eps-guidance-analyst-blog-cm160802</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/conmeds-newest-educational-program-analyst-blog-cm157842">
      <guid isPermaLink="false">157842</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ytYv3UHzPhU/conmeds-newest-educational-program-analyst-blog-cm157842</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Conmed's Newest Educational Program - Analyst Blog</title>
      <description>Surgical devices and technology provider  Conmed Corporation  (  CNMD  ) recently announced plans to co-develop a sequence of educational programs along with  Exactech, Inc  . (  EXAC  ).&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/ytYv3UHzPhU" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 23 Jul 2012 20:12:11 Z</pubDate>
      <a10:updated>2012-07-23T17:11:58Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CNMD</nasdaq:tickers>
      <nasdaq:tickers>COV</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>SNN</nasdaq:tickers>
      <nasdaq:tickers>SYK</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/conmeds-newest-educational-program-analyst-blog-cm157842</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/conmeds-newest-educational-program-analyst-blog-cm157841">
      <guid isPermaLink="false">157841</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XaGp8I4VctE/conmeds-newest-educational-program-analyst-blog-cm157841</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Conmed's Newest Educational Program - Analyst Blog</title>
      <description>Surgical devices and technology provider  Conmed Corporation  (  CNMD  ) recently announced plans to co-develop a sequence of educational programs along with  Exactech, Inc  . (  EXAC  ).&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/XaGp8I4VctE" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 23 Jul 2012 20:11:50 Z</pubDate>
      <a10:updated>2012-07-23T17:12:05Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CNMD</nasdaq:tickers>
      <nasdaq:tickers>COV</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>SNN</nasdaq:tickers>
      <nasdaq:tickers>SYK</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/conmeds-newest-educational-program-analyst-blog-cm157841</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/hanger-orthopedic-now-hanger-inc-analyst-blog-cm147582">
      <guid isPermaLink="false">147582</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IDFVUoc6km0/hanger-orthopedic-now-hanger-inc-analyst-blog-cm147582</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Hanger Orthopedic Now Hanger Inc. - Analyst Blog</title>
      <description>Hanger Orthopedic Group Inc.  (  HGR  ) will henceforth be known as Hanger, Inc., effective June 8, 2012. Management announced that the previous name was limiting and the move is part of the&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/IDFVUoc6km0" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 12 Jun 2012 01:45:01 Z</pubDate>
      <a10:updated>2012-06-11T22:54:54Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CNMD</nasdaq:tickers>
      <nasdaq:tickers>EXAC</nasdaq:tickers>
      <nasdaq:tickers>HGR</nasdaq:tickers>
      <nasdaq:tickers>OFIX</nasdaq:tickers>
      <nasdaq:tickers>OMI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/hanger-orthopedic-now-hanger-inc-analyst-blog-cm147582</feedburner:origLink></item>
  </channel>
</rss>
